161 related articles for article (PubMed ID: 31739939)
21. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group.
Tsang RW; Campbell BA; Goda JS; Kelsey CR; Kirova YM; Parikh RR; Ng AK; Ricardi U; Suh CO; Mauch PM; Specht L; Yahalom J
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):794-808. PubMed ID: 29976492
[TBL] [Abstract][Full Text] [Related]
22. [Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period)].
Jakó J; Szerafin L; Nagy P
Orv Hetil; 2005 Mar; 146(10):461-9. PubMed ID: 15835344
[TBL] [Abstract][Full Text] [Related]
23. Biannual report of the Cochrane Haematological Malignancies Group.
Trelle S; Higgins G; Kober T; Engert A
J Natl Cancer Inst; 2004 Aug; 96(15):E2. PubMed ID: 15292394
[No Abstract] [Full Text] [Related]
24. Epoetin alfa therapy for patients with hematologic malignancies and mild anemia.
Straus DJ
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S13-7. PubMed ID: 14556671
[TBL] [Abstract][Full Text] [Related]
25. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
Dilek I; Ayakta H; Demir C; Meral C; Ozturk M
Clin Lab Haematol; 2005 Feb; 27(1):51-5. PubMed ID: 15686508
[TBL] [Abstract][Full Text] [Related]
26. The role of radioimmunotherapy in bone marrow transplantation.
Corcoran MC; Press OW; Matthews DC; Appelbaum FR; Bernstein ID
Curr Opin Hematol; 1996 Nov; 3(6):438-45. PubMed ID: 9372115
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of a novel dose fractionation strategy in TMI/TMLI.
Bao Z; Zhao H; Wang D; Gong J; Zhong Y; Xiong Y; Deng D; Xie C; Liu A; Wang X; Liu H
Radiat Oncol; 2018 Dec; 13(1):248. PubMed ID: 30558631
[TBL] [Abstract][Full Text] [Related]
28. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.
Illidge T; Specht L; Yahalom J; Aleman B; Berthelsen AK; Constine L; Dabaja B; Dharmarajan K; Ng A; Ricardi U; Wirth A;
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):49-58. PubMed ID: 24725689
[TBL] [Abstract][Full Text] [Related]
29. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.
Pulte D; Gondos A; Brenner H
J Natl Cancer Inst; 2008 Sep; 100(18):1301-9. PubMed ID: 18780868
[TBL] [Abstract][Full Text] [Related]
30. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
31. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-6. Burkitt lymphoma (BL).
Ishizawa K
Int J Hematol; 2019 Sep; 110(3):265-271. PubMed ID: 31297687
[No Abstract] [Full Text] [Related]
32. [Immune-checkpoint inhibitors in hematologic malignancies].
Maruyama D
Rinsho Ketsueki; 2016; 57(11):2381-2387. PubMed ID: 27941289
[TBL] [Abstract][Full Text] [Related]
33. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group.
Maraldo MV; Dabaja BS; Filippi AR; Illidge T; Tsang R; Ricardi U; Petersen PM; Schut DA; Garcia J; Headley J; Parent A; Guibord B; Ragona R; Specht L
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):144-52. PubMed ID: 25670544
[TBL] [Abstract][Full Text] [Related]
34. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities.
Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P
South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700
[TBL] [Abstract][Full Text] [Related]
35. Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies.
Psaltopoulou T; Sergentanis TN; Ntanasis-Stathopoulos I; Tzanninis IG; Riza E; Dimopoulos MA
Int J Cancer; 2019 Jul; 145(2):347-359. PubMed ID: 30614529
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of hematological malignancies.
Rodriguez-Abreu D; Bordoni A; Zucca E
Ann Oncol; 2007 Jan; 18 Suppl 1():i3-i8. PubMed ID: 17311819
[No Abstract] [Full Text] [Related]
37. Second biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Bohlius J; Trelle S; Engert A
J Natl Cancer Inst; 2005 Apr; 97(7):E1. PubMed ID: 15812063
[No Abstract] [Full Text] [Related]
38. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
39. Frequency of hematologic malignancies in the population of Arica, Chile.
Pérez GB; Calaf GM; Villalba MTM; Prieto KS; Burgos FC
Oncol Lett; 2019 Nov; 18(5):5637-5643. PubMed ID: 31612068
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
